K. Patel

Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.

N. Dhanesha, Mukul R Jain, R. Bahekar, 2013, Canadian journal of physiology and pharmacology.

Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.

B. Srivastava, Mukul R Jain, Brijesh Kumar Srivastava, 2014, Canadian journal of physiology and pharmacology.

Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.

N. Dhanesha, Mukul R Jain, R. Bahekar, 2013, European journal of pharmacology.

Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.

T. Gandhi, N. Dhanesha, K. Patel, 2013 .

Pharmacological characterization of ZYDPLA1, a novel long‐acting dipeptidyl peptidase‐4 inhibitor

H. Patel, Mukul R Jain, P. Jadav, 2015, Journal of diabetes.

Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake.

Mukul R Jain, R. Bahekar, A. Joharapurkar, 2016, Canadian journal of physiology and pharmacology.

Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia

A. Joharapurkar, V. Patel, S. Kshirsagar, 2015, Drug Research.

Therapeutic potential of coagonists of glucagon and GLP-1.

Mukul R Jain, A. Joharapurkar, V. Patel, 2015, Cardiovascular & hematological agents in medicinal chemistry.